

# Clinical Criteria

<b>Subject:</b>	Viltepso (viltolarsen) – NY Medicaid		
<b>Document #:</b>	ING-CC-0172 - NY	<b>Publish Date:</b>	04/01/2022
<b>Status:</b>	New	<b>Last Review Date:</b>	02/25/2022

## Table of contents

<a href="#">Overview</a>	<a href="#">Coding</a>	<a href="#">References</a>
<a href="#">Clinical criteria</a>	<a href="#">Document history</a>	

## Overview

This document addresses the use of Viltepso (viltolarsen) (NS-065/NCNP-01), a phosphorodiamidate morpholino oligomer antisense oligonucleotide, in the treatment of Duchenne muscular dystrophy (DMD) with a mutation amenable to exon 53 skipping. Viltepso was approved under accelerated approval based on an increase in dystrophin production in skeletal muscle. Continued approval for DMD may be contingent upon verification and description of clinical benefit in a confirmatory trial (Viltepso label).

DMD is a genetic disorder characterized by decrease in muscle mass over time, including progressive damage and weakness of facial, limb, respiratory and heart muscles. In DMD patients, dystrophin, a protein that is present in skeletal and heart muscles allowing the muscles to function properly, is either absent or found in very small amounts. In theory, exon 53 skipping allows for the creation of a shorter-than-normal, but partially functional, dystrophin protein in patients with a specific type of DMD mutation. Exon 53 skipping is applicable in those with deletions in exons 45-52, 47-52, 48-52, 49-52, 50-52 and 52.

Viltepso (viltolarsen) was studied in a phase II, multi center, 2-period, randomized, placebo-controlled, dose finding study in ambulant boys ages 4-9 years of age with DMD (NCT02740972). Inclusion criteria incorporated ambulation status – patients were required to be ambulatory – and the ability to complete the following assessments: time to stand from supine, time to run/walk 10 m, and time to climb 4 stairs. While primary outcome measures were centered around adverse events, dystrophin protein in muscle and drug concentration in plasma, secondary outcomes included 6-minute walk test (6MWT), change in time to climb 4 stairs (TTCLIMB), change in time to run/walk 10 meters (TTRW), change in time to stand (TTSTAND) and North Star Ambulatory Assessment results (NSAA). The secondary outcomes were measured against matched controls in an external comparator group provided by the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS). (Clemens 2020)

An extension trial of NCT02740972 (NCT03167255) is currently ongoing in boys 4-10 years with primary outcomes of change in TTSTAND as well as adverse events. This study has an estimated primary completion date of October 2021 and an estimated study completion date of January 2022.

Finally, recruiting is ongoing for the Viltepso phase 3 study (NCT04060199; RACER53 trial). The phase 3 study is intended to assess efficacy and safety. Inclusion criteria are: male, age 4-7 (between  $\geq 4$  years and  $< 8$  years); confirmed DMD amenable to exon 53 skipping; able to walk independently without assistive devices; TTSTAND  $< 10$  seconds; stable dose of glucocorticoid for at least 3 months prior to study inclusion; other inclusion criteria may apply. Primary endpoint is the change in TTSTAND at 48 weeks of treatment. Secondary outcome measures include change in TTRW, 6MWT, NSAA, TTCLIMB and hand-held dynamometer. This study's estimated completion date is December 2024.

Viltepso (viltolarsen) is administered at a dose of 80 mg/kg via a weekly intravenous infusion. Although kidney toxicity was not observed in clinical studies with Viltepso, it was observed in animals who had received viltolarsen. Therefore, kidney function should be monitored in patients taking Viltepso. Because serum creatinine may not be a reliable measure of kidney function in DMD patients, other measures should be monitored. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before

<https://providerpublic.empireblue.com>

Empire BlueCross BlueShield HealthPlus is the trade name of HealthPlus HP, LLC, an independent licensee of the Blue Cross and Blue Shield Association.

NYEPEC-3244-22 April 2022

starting Viltepsso. Urine dipstick should be monitored every month; serum cystatin C and urine protein-to-creatinine ratio should be monitored every 3 months. In the event of persistent elevation in serum cystatin C or proteinuria, the patient should be referred to a pediatric nephrologist for further evaluation.

## Clinical criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Viltepsso (viltolarsen)

Initial requests for Viltepsso (viltolarsen) may be approved if the following criteria are met:

- I. Individual has a confirmed diagnosis of Duchenne muscular dystrophy (DMD); **AND**
- II. Documentation is provided that individual has a genetic mutation that is amenable to exon 53 skipping; **AND**
- III. Individual is age 4-9 years (NCT02740972) (Clemens 2020); **AND**
- IV. Individual is using a corticosteroid; **AND**
- V. Documentation indicates kidney function testing prior to starting therapy; **AND**
- VI. Individual will not use with any other exon skipping agents for DMD (including but not limited to Vyondys 53).

Continuation of therapy with Viltepsso (viltolarsen) may be approved if the following criterion are met:

Criteria above were met at initiation of therapy

**Approval Duration:** 6 months

Requests for Viltepsso (viltolarsen) may not be approved when the criteria above are not met and for all other indications.

## Quantity Limits

### Viltepsso (viltolarsen) Quantity Limits

Drug	Limit
Viltepsso (viltolarsen)	80 mg/kg once weekly

## Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### HCPCS

**J1427** Injection, viltolarsen, 10 mg

### ICD-10 Diagnosis

**G71.01** Duchenne or Becker muscular dystrophy

## Document history

Reviewed: 02/25/2022

Document History:

- 02/25/2022 - New York specific policy created based on guidance released from NYSDOH. Effective 04/01/2022.
- 08/20/2021 – Annual Review: No changes. Coding reviewed: No changes.
- 08/01/2021 – Administrative update to add documentation.
- 08/21/2020 – Annual Review: First review of Viltepso (viltolarsen); New clinical criteria for Viltepso; new quantity limit for Viltepso. Coding reviewed: Added HCPCS J3490, J3590, C9399, All diagnosis pend. Effective 1/1/21 Added HCPCS C9071, Removed C9399. Added ICD-10-CM G71.01. Effective 4/1/2021- Added HCPCS J1427. Removed J3490, J3590, C9071. Removed All diagnosis pend.
- 02/21/2020 – Select Review – Preliminary Review (pre-FDA approval) of viltolarsen

## References

1. Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. *Ad Drug Del Rev.* 2015; 87:140-107.
2. Watanabe N, Nagata T, Satou Y, et.al. NS-065/NCNP-01: An antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne Muscular Dystrophy. *Molecular Therapy: Nucleic Acids.* 2018; 13:442-449.
3. Clemens PR, Rao VK, Connolly AM, et.al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne Muscular Dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial. *JAMA Neurol.* May 2020. doi:10.1001/jamaneurol.2020.1264.
4. Viltepso [package insert]. Paramus, NJ; NS Pharma, Inc; 2020.
5. “New York State Medicaid Update – January 2022 Volume 38 – Number 1”. New York State Department of Health, 01 Feb. 2022, [https://health.ny.gov/health\\_care/medicaid/program/update/2022/no01\\_2022-01.htm](https://health.ny.gov/health_care/medicaid/program/update/2022/no01_2022-01.htm)

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association